EA201390070A1 - Лечение расстройств, вызванных l-dopa, дофаминовым агонистом и/или усилителем дофамина - Google Patents

Лечение расстройств, вызванных l-dopa, дофаминовым агонистом и/или усилителем дофамина

Info

Publication number
EA201390070A1
EA201390070A1 EA201390070A EA201390070A EA201390070A1 EA 201390070 A1 EA201390070 A1 EA 201390070A1 EA 201390070 A EA201390070 A EA 201390070A EA 201390070 A EA201390070 A EA 201390070A EA 201390070 A1 EA201390070 A1 EA 201390070A1
Authority
EA
Eurasian Patent Office
Prior art keywords
dopamine
dopa
treatment
amplifier
agonist
Prior art date
Application number
EA201390070A
Other languages
English (en)
Inventor
Патрик Александер Хоусон
Original Assignee
ФИТОФАРМ ПиЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ФИТОФАРМ ПиЭлСи filed Critical ФИТОФАРМ ПиЭлСи
Publication of EA201390070A1 publication Critical patent/EA201390070A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Addiction (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Одно или несколько средств, выбранных из фуростановых, фуростеновых, спиростановых и спиростеновых A/B-цисстероидных сапогепинов и их сложноэфирных, эфирных, кетонных и гликозилированных форм, включая их производные с открытым Е и/или F кольцом, применяют для лечения или предупреждения расстройств, вызванных L-DOPA, дофаминовым агонистом и/или усилителем дофамина, таких как вызванная L-DOPA дискинезия (LID), которая является побочным эффектом терапий с L-DOPA, дофаминовым агонистом и/или усилителем дофамина, например, для болезни Паркинсопа. Средство согласно настоящему изобретению может быть введено совместно с терапевтическим средством для лечения болезни Паркинсона или другого дофаминчувствительного расстройства.
EA201390070A 2010-07-20 2011-07-20 Лечение расстройств, вызванных l-dopa, дофаминовым агонистом и/или усилителем дофамина EA201390070A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36601510P 2010-07-20 2010-07-20
PCT/GB2011/051376 WO2012010896A1 (en) 2010-07-20 2011-07-20 Treatment of l-dopa, dopamine agonist and/or dopamine enhancer induced disorders

Publications (1)

Publication Number Publication Date
EA201390070A1 true EA201390070A1 (ru) 2013-09-30

Family

ID=44583771

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201390070A EA201390070A1 (ru) 2010-07-20 2011-07-20 Лечение расстройств, вызванных l-dopa, дофаминовым агонистом и/или усилителем дофамина

Country Status (13)

Country Link
US (1) US20130210786A1 (ru)
EP (1) EP2595621A1 (ru)
JP (1) JP2013543482A (ru)
KR (1) KR20130043197A (ru)
CN (1) CN103189056A (ru)
AU (1) AU2011281336B2 (ru)
BR (1) BR112013001422A2 (ru)
CA (1) CA2805693A1 (ru)
EA (1) EA201390070A1 (ru)
MX (1) MX2013000760A (ru)
SG (1) SG187090A1 (ru)
WO (1) WO2012010896A1 (ru)
ZA (1) ZA201301231B (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU20110244A7 (es) * 2011-12-27 2013-08-29 Ct De Investigación Y Desarrollo De Medicamentos Cidem Sistemas espiroesteroidales con efectos neuroactivos y anti-inflamatorios
ES2715028T3 (es) 2012-06-05 2019-05-31 Neuroderm Ltd Composiciones que comprenden apomorfina y ácidos orgánicos y sus usos
WO2016014242A1 (en) * 2014-07-21 2016-01-28 Spriaso Llc Compositions comprising bioreversible derivatives of hydroxy n-substituted-2-aminotetralins, dosage forms, and related methods
JP2017008044A (ja) * 2015-06-22 2017-01-12 学校法人 久留米大学 ドーパミンシグナル伝達の抑制剤
CN105106230A (zh) * 2015-08-16 2015-12-02 南京华宽信息咨询中心 一种单胺氧化酶mao抑制剂及其应用
MX2022001121A (es) * 2019-07-29 2022-02-16 Peptron Inc Composicion farmaceutica para el tratamiento de la disquinesia inducida por levodopa o para la supresion de la progresion de la misma.
WO2021141426A1 (ko) 2020-01-08 2021-07-15 건국대학교 글로컬산학협력단 리수리드 화합물을 유효성분으로 포함하는 취약 x 증후군 또는 관련 발달 장애 치료용 조성물
CA3187582A1 (en) * 2020-08-17 2022-02-24 Fotios M. Plakogiannis Pharmaceutical compositions and methods for treating parkinson's disease
CN115282156A (zh) * 2022-09-05 2022-11-04 广东海洋大学 知母皂苷元在制备防治帕金森病的药物中的应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA985172A (en) 1972-10-06 1976-03-09 Dushan M. Dvornik Compositions and methods for reducing blood cholesterol
EP0102416A1 (en) 1982-08-23 1984-03-14 Nutrisearch Company Blends of egg albumen and whey protein of improved gel strength
US4680289A (en) 1985-06-05 1987-07-14 Progenics, Inc. Treatment of obesity and diabetes using sapogenins
WO1992009281A2 (en) * 1990-11-24 1992-06-11 Beecham Group Plc Use of paroxetine for the treatment of senile dementia, bulimia, migraine or anorexia
AU749638B2 (en) 1997-03-17 2002-06-27 Btg International Limited Therapeutic compositions
CN1131237C (zh) 1997-09-26 2003-12-17 中国人民解放军军事医学科学院放射医学研究所 甾体皂甙防治老年性痴呆的用途及新的甾体皂甙
TR200002774T2 (tr) * 1998-03-26 2001-06-21 Phytopharm Plc Alzheimer hastalığının tedavisi için steroit sapogenler ve bunların türevleri
GB9923076D0 (en) 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB9905275D0 (en) 1999-03-08 1999-04-28 Phytopharm Ltd Treatment of conditions associated with membrane-bound receptors and their function
NZ509739A (en) 1998-09-15 2003-10-31 Btg Int Ltd A cyclic ester of (R)-3-hydroxybutyrate useful for increasing cardiac efficiency
GB2347676A (en) * 1999-03-08 2000-09-13 Phytopharm Plc Screening method
GB9923078D0 (en) 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB9923077D0 (en) 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB0000228D0 (en) 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
GB0107822D0 (en) 2001-03-28 2001-05-23 Phytopharm Plc Sapogenin derivatives their synthesis and use methods based upon their use
RU2332999C2 (ru) * 2002-03-27 2008-09-10 ФИТОФАРМ ПиЭлСи Терапевтические способы и применения сапогенинов и их производных
US20050130948A1 (en) * 2002-03-27 2005-06-16 Daryl Rees Therapeutic methods and uses of sapogenins and their derivatives
AU2003229877B8 (en) * 2002-03-27 2008-06-12 Phytopharm Plc Theraputic methods and uses of sapogenins and their derivatives
GB0409567D0 (en) 2004-04-28 2004-06-02 Phytopharm Plc Chemical compounds
GB0424528D0 (en) 2004-11-05 2004-12-08 Phytopharm Plc Chemical compounds
US20070041924A1 (en) * 2005-08-19 2007-02-22 Bioderm Research Sebum Control Compositions Based on Saponins and Sapogenins
WO2010084356A1 (en) * 2009-01-24 2010-07-29 Phytopharm Plc Treatment of neurotrophic factor mediated disorders

Also Published As

Publication number Publication date
EP2595621A1 (en) 2013-05-29
KR20130043197A (ko) 2013-04-29
AU2011281336A1 (en) 2013-01-31
CN103189056A (zh) 2013-07-03
US20130210786A1 (en) 2013-08-15
BR112013001422A2 (pt) 2019-09-24
ZA201301231B (en) 2014-04-30
SG187090A1 (en) 2013-02-28
JP2013543482A (ja) 2013-12-05
WO2012010896A1 (en) 2012-01-26
AU2011281336B2 (en) 2015-03-05
MX2013000760A (es) 2013-10-28
CA2805693A1 (en) 2012-01-26

Similar Documents

Publication Publication Date Title
EA201390070A1 (ru) Лечение расстройств, вызванных l-dopa, дофаминовым агонистом и/или усилителем дофамина
SA518392101B1 (ar) ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ
EA201890641A3 (ru) Стимуляторы sgc
MY180626A (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
BR112015020466A8 (pt) inibidores de cdc7, seus usos, e composição farmacêutica
EA201590748A1 (ru) Противовирусные соединения против rsv
EA201001331A1 (ru) ГЕТЕРОЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗ c-kit И PDGFR
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
UA109878C2 (uk) Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти)
NZ702050A (en) 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof
EA201200473A1 (ru) Замещенные (гетероарилметил)тиогидантоины
EA200801551A1 (ru) Применение сульфонамидных производных в лечении расстройств метаболизма и нервной системы
EA201170349A1 (ru) Модуляторы mif
EA201270480A1 (ru) Новые соединения
MA32485B1 (fr) Derives de pyridazine en tant qu'inhibiteurs de smo
ECSP088852A (es) Azolopirimidinas como inhibidores de la actividad canabinoidea 1
EA201270767A1 (ru) Терапия на основе лигандов хемосенсорных рецепторов
MX368903B (es) Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
MX2017005861A (es) Metodos para el control transcripcional objetivo en regiones del super mejorador.
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
EA201200046A1 (ru) Новые соединения, фармацевтическая композиция и связанные с ними способы
MX2020011099A (es) Compuestos, composiciones farmaceuticas y metodos de uso de agonistas de ppar.
EA202091020A1 (ru) Замещенные имидазопиридинамиды и их применение
EA201791225A1 (ru) Композиции и способы применения солабегрона с модифицированным высвобождением при симптомах нижних мочевых путей
EA201790315A1 (ru) Модуляторы x-рецепторов печени